Immuno-Oncology Clinical Trials Market - Global Industry Analysis

Immuno-Oncology Clinical Trials Market- By Design (Interventional Trials and Observational Trials), By Phase (Phase I, Phase II, Phase III, and Phase IV), By Indication (Solid Tumors and Hematological Cancer), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2028

Published Date: 08-Nov-2021 Category: Healthcare Report Format : PDF Pages: 187 Report Code: ZMR-6815 Status : Published

The global Immuno-Oncology Clinical Trials Market accrued earnings worth approximately 5.4 (USD Billion) in 2020 and is predicted to gain revenue of about 15.6 (USD Billion) by 2028, is set to record a CAGR of nearly 13.7% over the period from 2021 to 2028.

Description

The global Immuno-Oncology Clinical Trials Market accrued earnings worth approximately 5.4 (USD Billion) in 2020 and is predicted to gain revenue of about 15.6 (USD Billion) by 2028, is set to record a CAGR of nearly 13.7% over the period from 2021 to 2028. The report offers assessment and analysis of the Immuno-Oncology Clinical Trials Market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Global Immuno-Oncology Clinical Trials Market

Immuno-oncology Clinical Trials Market: Synopsis

Design and analysis of immuno-oncology clinical trials has been driven by efficiency patterns and toxicity observed in chemotherapy as well as other targeted agents. This, in turn, helps in completely informing clinical trial design as well as guide therapeutic decision making in immuno-oncology. Breakthroughs in immuno-oncology have brought a paradigm shift in cancer therapies and drug development and this is likely to crop up need for carrying out more of immuno-oncology clinical trials. However, there has been a big task for conducting these trials due to rapidly emerging landscape of healthcare industry. Apart from this, design & analysis of these clinical trials are facing huge challenge in terms of non-proportional hazards patterns translated into Kaplan-Meier curves encompassed by end-points referred as time to event end-points. Furthermore, researchers have devised new immunotherapy strategies for addressing concerns pertaining to failure of immuno-oncology clinical trials, thereby paving way for expansion of immuno-oncology clinical trials market. Moreover, breakthroughs in immuno-oncology clinical trial strategies have resulted in development of effective drugs for treating immuno-oncology disorders.

Furthermore, immune checkpoint inhibitors have strongly impacted oncology domain resulting in spike in clinical trial enrollment for clinical trials supported by rise in its approval by authorities such as FDA. For the record, in 2016, there were over 800 immuno-oncology clinical tests performed and more than 1, 55,000 patients enrolled for clinical trials on myriad kinds of combinations of immuno-oncology drugs.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Immuno-oncology Clinical Trials Market: Growth Drivers

With immunotherapy adding a new dimension to cancer treatment and becoming a major pillar in oncotherapeutics armamentarium, market for Immuno-oncology Clinical Trials is likely to gain traction in years to come. Massive acceptance of targeted drug treatment methods and breakthroughs in immuno-oncology will shape growth sphere of Immuno-oncology Clinical Trials industry in ensuing years. Furthermore, immuno-oncology agents harvest exceptional anti-tumor mechanisms and favorably influence host immune systems, thereby resulting into positive immune responses. Moreover, these aspects have led to optimal integration of immunotherapy into immuno-oncology clinical trials. This is likely to enlarge scope of growth for immuno-oncology clinical trials industry in span of next few years.

Reportedly, immuno-oncology clinical trials contribute nearly over one-third of total oncology clinical trials, thereby playing a major role in impacting returns for immuno-oncology clinical trials market. Rise in incidence of cancer has forced biotech & pharma firms to carry out more immuno-oncology clinical tests, thereby accounting for major chunk of revenue share of immuno-oncology clinical trials market.

Regional Landscape

North American Market To Reach Highest Peak Of Growth By 2028

Expansion of immuno-oncology clinical trials market in North America over forecast timespan can be credited to surge in demand for personalized drugs to be used in new cancer treatments. In addition to this, large budget allocation for cancer research activities by government as well as private firms is expected to lead to increment in number of immuno-oncology clinical trials in sub-continent. This is likely to augment market profitability in region. For the record, North America had accounted for nearly 52% of overall market revenue share in 2020 and is projected to continue its major contributions towards overall market proceeds even in next seven years.

Competitive Landscape

Key participants profiled in study and impacting business landscape are Medpace Holdings, Inc., AstraZeneca plc, Novartis AG, Syneous Health, and Exscientia.

The global Immuno-Oncology Clinical Trials Market is segmented as follows:

By Design

  • Observational Trials
  • Interventional Trials

By Phase

  • Phase I
  • Phase IV
  • Phase II
  • Phase III

By Indication

  • Solid Tumors
  • Hematological Cancer

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. Immuno-Onculogy Clinical Trials Market, 2018–2028(USD Billion)
    • 2.2. Immuno-Onculogy Clinical Trials Market: Snapshot
  • Chapter 3. Global Immuno-Onculogy Clinical Trials Market– Industry Analysis
    • 3.1. Immuno-Onculogy Clinical Trials Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Huge adoption of targeted drug therapy modes and breakthroughs in immuno-onculogy will nourish & protrude growth of Immuno-onculogy Clinical Trials industry in ensuing years.
      • 3.2.2. Surge in number of cancer cases has compelled biotech & pharma firms to perform more immuno-onculogy clinical tests, thereby contributing humungously towards immuno-onculogy clinical trials market size.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Design
      • 3.4.2. Market attractiveness analysis By Phase
      • 3.4.3. Market attractiveness analysis By Indication
  • Chapter 4. Global Immuno-Onculogy Clinical Trials Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Immuno-Onculogy Clinical Trials Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Immuno-Onculogy Clinical Trials Market– Design Analysis
    • 5.1. Global Orthopedic Soft Tissue Repair Market overview: By Design
      • 5.1.1. Global Orthopedic Soft Tissue Repair Market share, By Design, 2020 and 2028
    • 5.2. Observational Trials
      • 5.2.1. Global Orthopedic Soft Tissue Repair Marketby Observational Trials, 2018–2028(USD Billion)
    • 5.3. Interventional Trials
      • 5.3.1. Global Orthopedic Soft Tissue Repair Market by Interventional Trials, 2018–2028(USD Billion)
  • Chapter 6. Global Immuno-Onculogy Clinical Trials Market– Indication Analysis
    • 6.1. Global Orthopedic Soft Tissue Repair Market overview: By Indication
      • 6.1.1. Global Orthopedic Soft Tissue Repair Market share, By Indication, 2020 and 2028
    • 6.2. Sulid Tumors
      • 6.2.1. Global Orthopedic Soft Tissue Repair Marketby Sulid Tumors, 2018–2028(USD Billion)
    • 6.3. Hematulogical Cancer
      • 6.3.1. Global Orthopedic Soft Tissue Repair Market by Hematulogical Cancer, 2018–2028(USD Billion)
  • Chapter 7. Global Orthopedic Soft Tissue Repair Marketoverview: By Phase
    • 7.1. Global Orthopedic Soft Tissue Repair Marketshare, By Phase, 2020 and 2028
    • 7.2. Phase I
      • 7.2.1. Global Orthopedic Soft Tissue Repair Marketby Phase I , 2018–2028(USD Billion)
    • 7.3. Phase IV
      • 7.3.1. Global Orthopedic Soft Tissue Repair Marketby Phase IV, 2018–2028(USD Billion)
    • 7.4. Phase II
      • 7.4.1. Global Orthopedic Soft Tissue Repair Marketby Phase II, 2018–2028(USD Billion)
    • 7.5. Phase III
      • 7.5.1. Global Orthopedic Soft Tissue Repair Marketby Phase III, 2018–2028(USD Billion)
  • Chapter 8. Company Profiles
    • 8.1. Medpace Huldings, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfulio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. AstraZeneca plc
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfulio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Novartis AG
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfulio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Development
    • 8.4. Syneous Health
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfulio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Development
    • 8.5. Exscientia
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfulio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development

Table Of Figures

List of Figures

1. Market research Type
2. Market research methodology
3. Global Immuno-Oncology Clinical Trials Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global Immuno-Oncology Clinical Trials Marketattractiveness, By Design
6. Global Immuno-Oncology Clinical Trials Marketattractiveness, By Phase
7. Global Immuno-Oncology Clinical Trials Marketattractiveness, By Indication
8. Global Immuno-Oncology Clinical Trials Marketshare by Design ,2020 and 2028 (USD Billion)
9. Global Immuno-Oncology Clinical Trials Marketby Observational Trials, 2018–2028(USD Billion)
10. Global Immuno-Oncology Clinical Trials Marketby Interventional Trials, 2018–2028(USD Billion)
11. Global Immuno-Oncology Clinical Trials Marketshare by Indication ,2020 and 2028 (USD Billion)
12. Global Immuno-Oncology Clinical Trials Marketby Solid Tumors, 2018–2028(USD Billion)
13. Global Immuno-Oncology Clinical Trials Marketby Hematological Cancer, 2018–2028(USD Billion)
14. Global Immuno-Oncology Clinical Trials Marketshare by Phase,2020 and 2028 (USD Billion)
15. Global Immuno-Oncology Clinical Trials Marketby Phase I,  2018–2028(USD Billion)
16. Global Immuno-Oncology Clinical Trials Marketby Phase IV, 2018–2028(USD Billion)
17. Global Immuno-Oncology Clinical Trials Marketby Phase II, 2018–2028(USD Billion)
18. Global Immuno-Oncology Clinical Trials Marketby Phase III, 2018–2028(USD Billion)
19. Global Immuno-Oncology Clinical Trials Marketshare, by Region, 2020 and 2028
20. North America Immuno-Oncology Clinical Trials Market, 2018–2028(USD Billion)
21. Europe Immuno-Oncology Clinical Trials Market, 2018–2028(USD Billion)
22. Asia Pacific Immuno-Oncology Clinical Trials Market, 2018–2028(USD Billion)
23. Latin America Immuno-Oncology Clinical Trials Market, 2018–2028(USD Billion)
24. The Middle East and Africa Immuno-Oncology Clinical Trials Market, 2018–2028(USD Billion)
 


Table Of Tables

List of Tables

1. Global Immuno-Oncology Clinical Trials Market: snapshot
2. Drivers of the Immuno-Oncology Clinical Trials Market: impact analysis
3. North America Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
4. North America Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
5. North America Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
6. The U.S. Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
7. The U.S. Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
8. The U.S. Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
9. Rest of North America Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
10. Rest of North America Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
11. Rest of North America Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
12. Europe Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
13. Europe Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
14. Europe Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
15. UK Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
16. UK Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
17. UK Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
18. France Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
19. France Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
20. France Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
21. Germany Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
22. Germany Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
23. Germany Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
24. Rest of Europe Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
25. Rest of Europe Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
26. Rest of Europe Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
27. Asia Pacific Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
28. Asia Pacific Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
29. Asia Pacific Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
30. China Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
31. China Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
32. China Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
33. Japan Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
34. Japan Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
35. Japan Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
36. India Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
37. India Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
38. India Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
39. Rest of Asia Pacific Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
40. Rest of Asia Pacific Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
41. Rest of Asia Pacific Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
42. Latin America Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
43. Latin America Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
44. Latin America Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
45. Brazil Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
46. Brazil Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
47. Brazil Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
48. Rest of Latin America Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
49. Rest of Latin  America Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
50. Rest of Latin America Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
51. The Middle East and Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
52. The Middle East and Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
53. The Middle East and Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
54. Saudi Arabia Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
55. Saudi Arabia Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
56. Saudi Arabia Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
57. South Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
58. South Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
59. South Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)
60. Rest of the Middle East & Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Design  ,2018–2028(USD Billion)
61. Rest of the Middle East & Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Phase,2018–2028(USD Billion)
62. Rest of the Middle East & Africa Orthopedic Soft Tissue Repair  Marketrevenue, By Indication,2018–2028(USD Billion)


 
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

With immunotherapy adding a new facet to cancer treatment and becoming a major tool in oncotherapeutics armamentarium, market for Immuno-oncology Clinical Trials is likely to expand in years to come. Massive acceptance of targeted drug treatment methods and breakthroughs in immuno-oncology will shape growth dimensionality of Immuno-oncology Clinical Trials industry in forthcoming years. Furthermore, immuno-oncology agents yield exceptional anti-tumor mechanisms and have positive impact on host immune systems, thereby resulting into favorable immune responses. Moreover, these aspects have led to large integration of immunotherapy into immuno-oncology clinical tests. This is likely to extend scope of growth for immuno-oncology clinical trials market in span of couple of years.

Reportedly, immuno-oncology clinical trials contribute nearly over one-third of total oncology clinical trials, thereby playing a major role in impacting returns for immuno-oncology clinical trials market.   

According to Zion market research report, the global Immuno-Oncology Clinical Trials Market accrued earnings worth approximately 5.4 (USD Billion) in 2020 and is predicted to gain revenue of about 15.6 (USD Billion) by 2028, is set to record a CAGR of nearly 13.7% over the period from 2021 to 2028.

North America will contribute lucratively towards the regional market size over the projected timeline. The regional market surge is subject to surge in demand for personalized drugs to be used in new cancer treatments. In addition to this, large budget allocation for cancer research activities by government as well as private firms is expected to lead to increment in number of immuno-oncology clinical trials in sub-continent. This is likely to augment market profitability in region. For the record, North America had accounted for nearly 52% of overall market revenue share in 2020 and is projected to continue its major contributions towards overall market proceeds even in next seven years.  

The key market participants include Medpace Holdings, Inc., AstraZeneca plc, Novartis AG, Syneous Health, and Exscientia.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed